Clinical Trials

NewLink Genetics announced that it has entered into a clinical collaboration agreement with AstraZeneca to evaluate the combination of indoximod, NewLink Genetics’ small molecule IDO…
Read More...

AstraZeneca has announced positive top-line results of the Phase III, PINNACLE 4 trial in which Bevespi Aerosphere (glycopyrronium and formoterol fumarate 14.4/9.6 µg) demonstrated a…
Read More...

Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, announced that it has treated the first…
Read More...

Provention Bio announced that it has entered into agreements with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC to in-license two clinical-stage assets, PRV-6527…
Read More...

Regeneron Pharmaceuticals and Sanofi announced positive results from the Phase 3 CAFÉ study of DUPIXENT® (dupilumab) in adults with moderate-to-severe atopic dermatitis (AD) who are…
Read More...

Thrombolytic Science, LLC (TSI) announced the completion of a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy aimed at the treatment of clot-induced diseases…
Read More...

MilliporeSigma announced that Celonic AG, a Swiss contract development and manufacturing organization (CDMO), is upgrading its manufacturing facility with five of MilliporeSigma's…
Read More...

Kura Oncology announced positive topline results from a Phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell…
Read More...

IRX Therapeutics presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society…
Read More...

Midatech Pharma has announced the submission of a clinical trial application (CTA) for a first in human study of its MTD201 programme in carcinoid cancer and acromegaly. The…
Read More...

Roche announced results from the global phase III ALUR study showing that Alecensa® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85%…
Read More...

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, announced publication of positive data from a Phase 2 clinical trial…
Read More...

Regeneron Pharmaceuticals announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of…
Read More...

PharmaMar announced the start of a multicenter quadruple combination clinical study with Aplidin (plitidepsina), along with other compounds for the treatment of multiple myeloma.…
Read More...

Flex Pharma has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial in the US. The COMMEND trial will evaluate FLX-787, the Company’s co-activator of…
Read More...

Brainstorm Cell Therapeutics announced that the California Institute for Regenerative Medicine (CIRM) has awarded Brainstorm a grant of $16 million to support the pivotal Phase 3 study…
Read More...

BioLight Life Sciences announced successful results from its glaucoma insert VS101 ("Eye-D latanoprost insert") Phase 1/2a clinical trial, which demonstrated its ability to lower…
Read More...

Eli Lilly and Company has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia…
Read More...

Zydus announced the initiation of a phase II trial investigating ZYAN1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anemia associated…
Read More...

Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent…
Read More...